“The
Report Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 -
Off-patent Chemo-regimens to Retain Dominance Despite New Launches
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz”
GBI Research, a leading
business intelligence provider, has released its latest research
report: “Ovarian Cancer Therapeutics in Asia-Pacific Markets to
2020 - Off-patent Chemo-regimens to Retain Dominance Despite New
Launches”. The report provides estimates of the market size for
2013, along with forecasts until 2020 for the Asia-Pacific markets of
India, China, Australia and Japan. It also covers disease
epidemiology, treatment algorithms, treatment patterns, in-depth
analysis of clinical trials including failure rates and pipeline
analysis, and analysis of deals relevant to Ovarian Cancer (OC).
View Full Report at
http://www.marketresearchreports.biz/analysis/242400
Platinum-based chemotherapy,
predominantly the chemotherapy regimen paclitaxel and carboplatin, is
the standard of care for the treatment of platinum-sensitive OC (both
first-line and recurrent). The initial treatment is quite effective,
with the majority of patients entering remission. However, almost all
relapse, and after successive periods of remission and relapse either
die or progress to platinum-resistant disease, for which the
prognosis is poor. There is a clear gap in the market for maintenance
therapies, as well as for more effective treatment options in
platinum-resistant or refractory patients.
Although the current
developmental pipeline is quite crowded, efficacy with these
late-stage drugs has been poor, at best demonstrating minimal
improvements in progression-free survival, but not overall survival.
The promising investigational drug candidates olaparib and trebananib
are expected to gain approval during the forecast period. However,
even on approval they are not expected to have a high market
penetration, owing to their minimal therapeutic efficacy and
anticipated premium prices. As a result, the OC market in APAC is
expected not be driven by new drug approvals, but primarily by
inflation, and the increase in the prevalence of OC. Market revenue
is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.
Download Detail Report With
Complete TOC at
http://www.marketresearchreports.biz/sample/sample/242400
Despite the poor clinical
performance of current late-stage pipeline drugs, there is evidence
of continued interest in the OC market, with a high number of drug
candidates in the initial developmental pipeline, particularly at the
Preclinical phase. There is a wide range of novel molecular targets
distributed among these drug candidates, including growth factors,
serine/threonine protein kinases and tumor associated antigens. This
suggests a continued interest in introducing more targeted therapies
into the treatment of OC, the use of which in this indication lags
significantly behind that in others in oncology.
Scope
The report analyzes treatment
usage patterns, drug types available and pipeline and market
forecasts for OC. It covers and includes:
- A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis
- In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
- A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
- Discussion of the drivers and barriers for market growth
- In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals
Reasons
To Buy
The report will assist
business development and enable marketing executives to strategize
their product launches, by allowing them to:
- Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
- Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Pathophysiology
2.1.1 Ovarian Cancer – A
Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly
Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited Genetic
Mutations
2.3.3 Greater Number of
Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical
Conditions
2.4 Treatment Algorithm
2.4.1 Surgery
2.4.2 First-Line Chemotherapy
2.4.3 Maintenance Therapy
2.5 Recurrent Disease
3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated Liposomal
Doxorubicin
3.6 Yondelis
3.7 Avastin
Related
Reports
GBI Research, the leading
business intelligence provider, has released its latest research:
“Colorectal Cancer Therapeutics in Major Developed Markets to 2020
- Increased Uptake of High Priced Drugs to Offset the Impact of
Generics”, which provides in-depth analysis of the Colorectal
Cancer (CRC) therapeutics market in the eight major geographies of
the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The
report provides an estimation of the market size for 2013, along with
market forecast until 2020. It also covers disease epidemiology,
treatment algorithms, treatment patterns, in-depth pipeline analysis,
and deal analysis.
Scope
of the report
The report titled “The US
Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)”
provides an in-depth analysis of the United States chronic pain
therapy market (including medication, surgeries and therapies) with
detailed analysis of market sizing and growth and market share of the
various drugs involved in the treatment of chronic pain. The report
also assesses the key opportunities in the market and outlines the
factors that are and will be driving the growth of the industry.
Growth of the overall chronic pain therapy market has also been
forecasted for the period 2014-19, taking into consideration the
previous growth patterns, the growth drivers and the current and
future trends. Further, key players of the industry like Zogenix
Inc., Egalet Corporation and NektarTheropeutics are profiled.
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
E:
sales@marketresearchreports.biz
No comments:
Post a Comment